Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004852 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
A Phase 2 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004852: Completed Phase 2 study, sponsored by Glaxo Wellcome.
NCT00004852 is a Phase 2 study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004852, a Phase 2 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Efavirenz
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-09 |
| Phase | Phase 2 |
What the finished NCT00004852 record still lists
NCT00004852 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00004852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004852 about?
NCT00004852 is a clinical study titled "Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs". The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.
What is the current status of trial NCT00004852?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-09.
What interventions are being tested in trial NCT00004852?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Efavirenz (DRUG).
Who is sponsoring clinical trial NCT00004852?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia